vTv Therapeutics (VTVT) to Release Quarterly Earnings on Monday

vTv Therapeutics (NASDAQ:VTVT) is projected to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect vTv Therapeutics to post earnings of ($0.87) per share for the quarter.

vTv Therapeutics Stock Performance

VTVT opened at $14.85 on Friday. The stock has a 50-day moving average of $16.47 and a 200-day moving average of $15.31. The company has a market cap of $47.37 million, a PE ratio of -3.28 and a beta of 1.07. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on VTVT shares. StockNews.com initiated coverage on vTv Therapeutics in a research report on Tuesday, March 11th. They set a “sell” rating on the stock. Alliance Global Partners started coverage on vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.